Neoadyuvant High-dose of Ifosfamide and Concurrent Radiotherapy in Soft Tissue Sarcoma

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To study the activity and toxicity of a neoadjuvant regimen including high-dose ifosfamide in combination with radiotherapy, and subsequent surgery, in high-risk soft tissue sarcomas.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Grupo Espanol de Investigacion en Sarcomas
• Treatments: Ifosfamide; Isophosphamide mustard

Criteria

Inclusion Criteria:

1. Patients with Advanced Soft Tissue Sarcoma histological proven, potentially resected, located in extremities and trunk for one of the following histological subtypes: leiomyosarcoma, undifferentiated pleomorphic sarcoma, Synovial Sarcoma, Liposarcoma and malignant tumour of peripheral nerve sheath.

2. Primary tumour:

1. Size ³ 5 cm of diameter

2. Histological grade 2-3

3. Deep location

3. No distant metastases

4. Patients must have not been previously treated with Chemotherapy or Radiotherapy on the tumour area.

5. However patients are eligible with local relapse after previous surgery.

6. Patients must be £18 and ³ 65 years old.

7. Patients must have ECOG performance status 0 to 1

8. Patients must have measurable disease by Recist Criteria.

9. Absolute neutrophil count ³1,500/mm3, platelet count ³ 100,060 ml/min, creatinine, total bilirubin, ALT and AST £ 1.5 times the upper limit of normal

10. Signed informed consent prior to any study specific procedures

Exclusion Criteria:

1. Patients with cerebral metastasis

2. Pregnant or breast feeding patients.

3. Active infection or other concomitant severe illness.

4. Severe psychiatric illness which would not make possible the obtention of the informed consent

5. Concurrent treatment with other experimental drugs within 30 days prior to study entry.

6. History of previous treated or diagnosed cancer in the past 5 years, excepting basocellular cell skin cancer, cervix cancer in situ or superficial bladder carcinoma.